KR101622944B1 - α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ - Google Patents

α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ Download PDF

Info

Publication number
KR101622944B1
KR101622944B1 KR1020107025581A KR20107025581A KR101622944B1 KR 101622944 B1 KR101622944 B1 KR 101622944B1 KR 1020107025581 A KR1020107025581 A KR 1020107025581A KR 20107025581 A KR20107025581 A KR 20107025581A KR 101622944 B1 KR101622944 B1 KR 101622944B1
Authority
KR
South Korea
Prior art keywords
fsh
sialylation
alpha
rfsh
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107025581A
Other languages
English (en)
Korean (ko)
Other versions
KR20110005863A (ko
Inventor
이안 코팅햄
다니엘 플락신
리차드 보이드 화이트
Original Assignee
페링 인터내셔널 센터 에스 에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101622944(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 페링 인터내셔널 센터 에스 에이 filed Critical 페링 인터내셔널 센터 에스 에이
Publication of KR20110005863A publication Critical patent/KR20110005863A/ko
Application granted granted Critical
Publication of KR101622944B1 publication Critical patent/KR101622944B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020107025581A 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ Active KR101622944B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
US61/045,424 2008-04-16
EP08251528 2008-04-25
EP08251528.9 2008-04-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167012148A Division KR20160056960A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ

Publications (2)

Publication Number Publication Date
KR20110005863A KR20110005863A (ko) 2011-01-19
KR101622944B1 true KR101622944B1 (ko) 2016-05-23

Family

ID=39717519

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020107025581A Active KR101622944B1 (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ
KR1020197022294A Active KR102108377B1 (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ
KR1020167012148A Ceased KR20160056960A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ
KR1020187023820A Ceased KR20180095140A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ
KR1020177026920A Ceased KR20170110741A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020197022294A Active KR102108377B1 (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ
KR1020167012148A Ceased KR20160056960A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ
KR1020187023820A Ceased KR20180095140A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ
KR1020177026920A Ceased KR20170110741A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ

Country Status (29)

Country Link
US (6) US8951967B2 (enExample)
EP (7) EP3098234B1 (enExample)
JP (7) JP2011519359A (enExample)
KR (5) KR101622944B1 (enExample)
CN (3) CN105906702A (enExample)
AR (1) AR071479A1 (enExample)
AU (5) AU2009237479B2 (enExample)
BR (1) BRPI0910461B8 (enExample)
CA (1) CA2725257A1 (enExample)
CY (1) CY1115413T1 (enExample)
DK (6) DK4015527T3 (enExample)
ES (5) ES2629392T3 (enExample)
FI (4) FI4015527T3 (enExample)
FR (3) FR17C1020I2 (enExample)
HR (5) HRP20140535T1 (enExample)
HU (9) HUE071059T2 (enExample)
IL (2) IL208538A (enExample)
LT (8) LT3098234T (enExample)
MX (3) MX348622B (enExample)
NO (4) NO2017025I1 (enExample)
NZ (1) NZ588381A (enExample)
PL (6) PL3045471T3 (enExample)
PT (6) PT2808340T (enExample)
RU (3) RU2537268C2 (enExample)
SA (1) SA109300228B1 (enExample)
SI (6) SI3144318T1 (enExample)
TW (1) TWI488640B (enExample)
WO (1) WO2009127826A1 (enExample)
ZA (1) ZA201007373B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190133675A (ko) * 2017-03-29 2019-12-03 세벡 파마세우티컬스 게엠베하 안테너리 푸코실화가 감소된 재조합 당단백질

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
RS54214B2 (sr) 2010-09-29 2024-02-29 Ferring Bv Smeša za upotrebu u lečenju infertiliteta
CN103154243A (zh) 2010-10-15 2013-06-12 日本化学研究株式会社 糖链的非还原末端为甘露糖残基的糖蛋白的制造方法
ES2693273T3 (es) * 2011-03-31 2018-12-10 Ferring B.V. Preparación farmacéutica
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
JP6279466B2 (ja) * 2012-04-27 2018-02-14 Ｊｃｒファーマ株式会社 新規な発現ベクター
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
WO2016102436A1 (en) * 2014-12-22 2016-06-30 F. Hoffmann-La Roche Ag Cmp-dependent sialidase activity
HUE048757T2 (hu) 2015-04-17 2020-08-28 Ferring Bv FSH meddõség kezelésére
AU2016282916B2 (en) 2015-06-26 2022-01-20 Ferring B.V. Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
MA50034B1 (fr) 2017-09-01 2022-02-28 Ferring Bv Composition de stimulation ovarienne contrôlée
PL3787667T3 (pl) 2018-04-30 2025-07-28 Ferring B.V. Kompozycja do kontrolowanej stymulacji jajników
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
WO2021081670A1 (en) * 2019-11-01 2021-05-06 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
AU2022451605A1 (en) 2022-04-01 2024-09-26 Ferring B.V. Mixed protocol for treatment of infertility
KR20250016113A (ko) 2022-05-26 2025-02-03 훼링 비.브이. 남성 불임 치료를 위한 조성물 및 방법
MA71382A (fr) 2022-07-08 2025-04-30 Ferring B.V. Compositions et procédés d'insémination intra-utérine (iiu)
TW202504578A (zh) 2023-07-20 2025-02-01 荷蘭商輝凌責任有限公司 緩釋載藥微粒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035686A2 (en) * 2001-10-22 2003-05-01 Applied Research Systems Ars Holding N.V. Compositions of fsh with high sialylation degree and their use for the preparation of medicaments
US20060234352A1 (en) 2000-12-05 2006-10-19 Applied Research Systems Ars Holding N.V. Homogeneity and secretion of recombinant proteins in mammalian systems

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US6399336B1 (en) 1997-01-16 2002-06-04 Neose Technologies, Inc. Practical in vitro sialylation of recombinant glycoproteins
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
IL146252A0 (en) 1999-05-07 2002-07-25 Applied Research Systems Use of gonadotrophin in induction of folliculogenesis
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
EP1440157B1 (en) 2001-10-29 2012-01-25 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
EP1465987B1 (en) 2001-12-07 2008-01-23 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
DK1711834T3 (da) 2004-02-04 2010-11-29 Centre Nat Rech Scient Fremgangsmåde til screening af glycoform-specifikke antistoffer
AU2005215889B9 (en) 2004-02-13 2011-11-17 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
RS54214B2 (sr) 2010-09-29 2024-02-29 Ferring Bv Smeša za upotrebu u lečenju infertiliteta
ES2693273T3 (es) 2011-03-31 2018-12-10 Ferring B.V. Preparación farmacéutica
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
CA2945883A1 (en) 2014-04-18 2015-10-22 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234352A1 (en) 2000-12-05 2006-10-19 Applied Research Systems Ars Holding N.V. Homogeneity and secretion of recombinant proteins in mammalian systems
WO2003035686A2 (en) * 2001-10-22 2003-05-01 Applied Research Systems Ars Holding N.V. Compositions of fsh with high sialylation degree and their use for the preparation of medicaments

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Human Reproduction Vol.15(9):1898-1902 (2000)
Journal of Clinical Endocrinology and Metabolism Vol.79(3):756-759 (1994)*

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190133675A (ko) * 2017-03-29 2019-12-03 세벡 파마세우티컬스 게엠베하 안테너리 푸코실화가 감소된 재조합 당단백질
KR102605267B1 (ko) * 2017-03-29 2023-11-24 세벡 파마세우티컬스 게엠베하 안테너리 푸코실화가 감소된 재조합 당단백질

Also Published As

Publication number Publication date
PT3098234T (pt) 2024-10-21
LT3098234T (lt) 2024-09-10
HUS2500008I1 (hu) 2025-02-28
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
DK2268666T3 (da) 2014-05-12
EP4015527A1 (en) 2022-06-22
ES2629392T3 (es) 2017-08-09
EP3144318A1 (en) 2017-03-22
ZA201007373B (en) 2011-06-29
EP2722339A1 (en) 2014-04-23
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
NO2025006I1 (no) 2025-01-16
KR20160056960A (ko) 2016-05-20
RU2682270C2 (ru) 2019-03-18
RU2010141908A (ru) 2012-05-27
AU2017225020A1 (en) 2017-09-28
HRP20250313T1 (hr) 2025-05-09
AU2017204259B2 (en) 2017-08-17
JP2020040956A (ja) 2020-03-19
NO2017025I1 (no) 2017-06-06
ES2989729T3 (es) 2024-11-27
PL3098234T3 (pl) 2025-01-07
LTPA2017029I1 (lt) 2017-10-10
NO2025032I1 (no) 2025-07-14
EP2808340A1 (en) 2014-12-03
KR20110005863A (ko) 2011-01-19
US20160347811A1 (en) 2016-12-01
HUS1700025I1 (hu) 2017-06-28
PT2268666E (pt) 2014-06-25
SI2268666T1 (sl) 2014-07-31
EP3144318B1 (en) 2020-09-23
IL230571A (en) 2015-11-30
US8951967B2 (en) 2015-02-10
WO2009127826A1 (en) 2009-10-22
DK3045471T3 (en) 2017-06-26
CN105906702A (zh) 2016-08-31
FR17C1020I2 (fr) 2020-04-10
PT3045471T (pt) 2017-06-14
US20210332099A1 (en) 2021-10-28
HK1199039A1 (en) 2015-06-19
DK3098234T3 (da) 2024-10-21
FR17C1020I1 (enExample) 2020-04-10
HUE033830T2 (en) 2018-01-29
CN102066414A (zh) 2011-05-18
PL2268666T3 (pl) 2014-08-29
SI2808340T1 (sl) 2016-12-30
LTPA2025505I1 (enExample) 2025-02-10
LTPA2017018I1 (lt) 2017-06-26
BRPI0910461A2 (pt) 2018-03-27
US9546204B2 (en) 2017-01-17
RU2014141994A3 (enExample) 2018-05-28
PT4015527T (pt) 2025-04-10
AR071479A1 (es) 2010-06-23
PT3144318T (pt) 2020-11-04
EP2268666B1 (en) 2014-03-12
JP2024038000A (ja) 2024-03-19
FI3098234T3 (fi) 2024-10-31
DK4015527T3 (da) 2025-04-14
AU2009237479A1 (en) 2009-10-22
HUS1700036I1 (hu) 2017-10-30
US20110105398A1 (en) 2011-05-05
KR20180095140A (ko) 2018-08-24
KR20190092608A (ko) 2019-08-07
TW200948378A (en) 2009-12-01
HUE071059T2 (hu) 2025-07-28
FI4015527T3 (fi) 2025-04-29
JP2018021037A (ja) 2018-02-08
JP7316905B2 (ja) 2023-07-28
RU2014141994A (ru) 2016-05-10
DK3144318T3 (da) 2020-12-07
SI3098234T1 (sl) 2024-10-30
PL3144318T3 (pl) 2021-02-08
NZ588381A (en) 2012-05-25
AU2014203277B2 (en) 2017-04-06
HUE068565T2 (hu) 2025-01-28
TWI488640B (zh) 2015-06-21
US20240327487A1 (en) 2024-10-03
JP2017060476A (ja) 2017-03-30
HRP20161520T1 (hr) 2016-12-30
KR20170110741A (ko) 2017-10-11
EP3045471A1 (en) 2016-07-20
JP2015120696A (ja) 2015-07-02
EP3045471B1 (en) 2017-03-29
JP2011519359A (ja) 2011-07-07
HUE030652T2 (en) 2017-05-29
US20150065695A1 (en) 2015-03-05
AU2014203277C1 (en) 2017-07-27
US9771407B2 (en) 2017-09-26
FIC20250003I1 (fi) 2025-01-15
EP2268666A1 (en) 2011-01-05
HUS1700024I1 (hu) 2017-06-28
HUS2500029I1 (hu) 2025-07-28
BRPI0910461A8 (pt) 2018-10-16
FIC20250025I1 (fi) 2025-07-11
NO2017050I1 (no) 2017-09-28
EP4015527B1 (en) 2025-01-22
AU2009237479B2 (en) 2014-05-15
BRPI0910461B1 (pt) 2021-02-23
FR25C1003I1 (fr) 2025-02-28
PL3045471T3 (pl) 2017-10-31
LT3045471T (lt) 2017-07-10
CA2725257A1 (en) 2009-10-22
US11952407B2 (en) 2024-04-09
US20180079794A1 (en) 2018-03-22
SI3045471T1 (sl) 2017-07-31
EP3098234B1 (en) 2024-07-31
BRPI0910461B8 (pt) 2021-05-25
US10995128B2 (en) 2021-05-04
LT4015527T (lt) 2025-04-10
SI4015527T1 (sl) 2025-05-30
RU2745557C1 (ru) 2021-03-29
CN105906703A (zh) 2016-08-31
IL208538A (en) 2014-03-31
RU2537268C2 (ru) 2014-12-27
JP6762916B2 (ja) 2020-09-30
AU2017204259A1 (en) 2017-07-20
AU2017204258B2 (en) 2017-08-17
LTPA2025525I1 (enExample) 2025-07-25
HUE030652T4 (en) 2017-09-28
EP2808340B1 (en) 2016-08-17
ES3023526T3 (en) 2025-06-02
CY1115413T1 (el) 2017-01-04
AU2017225020B2 (en) 2019-11-14
HK1146284A1 (en) 2011-05-20
JP2022031652A (ja) 2022-02-22
LT2808340T (lt) 2016-11-10
SI3144318T1 (sl) 2020-12-31
PT2808340T (pt) 2016-11-21
MX348622B (es) 2017-06-22
PL2808340T3 (pl) 2017-02-28
HRP20241187T1 (hr) 2024-12-06
FR25C1025I1 (fr) 2025-09-19
AU2014203277A1 (en) 2014-07-24
KR102108377B1 (ko) 2020-05-08
HRP20170958T1 (hr) 2017-09-22
AU2017204258A1 (en) 2017-07-20
EP3098234A1 (en) 2016-11-30
SA109300228B1 (ar) 2014-04-08
MX355457B (es) 2018-04-19
IL208538A0 (en) 2010-12-30
ES2468318T3 (es) 2014-06-16
DK2808340T3 (en) 2016-12-05
JP6486310B2 (ja) 2019-03-20
RU2745557C3 (ru) 2021-12-10

Similar Documents

Publication Publication Date Title
KR101622944B1 (ko) α2,3- 및 α2,6-시알화를 포함하는 재조합 ＦＳＨ

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101115

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140407

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150819

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160217

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160509

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160516

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160516

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190515

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190515

Start annual number: 4

End annual number: 4

PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20200326

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

PR1001 Payment of annual fee

Payment date: 20200507

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20210507

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20220503

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20230508

Start annual number: 8

End annual number: 8